Juan Castelan-Vega

Dr. Juan Castelan-Vega

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Computational Biology and Chemistry
Verified
Journal Article
Closed access
AAAlicia Jimenez Alberto
Alicia Jimenez Alberto
RRRosa María Ribas-Aparicio
Rosa María Ribas-Aparicio
GAGerardo Aparicio-Ozores
Gerardo Aparicio-Ozores
JCJuan Castelan-Vega
Juan Castelan-Vega

29 July 2021 in Nucleosides, Nucleotides & Nucleic Acids
Verified
Journal Article
Closed access
AEAlejandro Escamilla-Gutiérrez
Alejandro Escamilla-Gutiérrez
RRRosa María Ribas-Aparicio
Rosa María Ribas-Aparicio
MCMaría Guadalupe Córdova-Espinoza
María Guadalupe Córdova-Espinoza
JCJuan Castelan-Vega
Juan Castelan-Vega
RNA aptamers are single-stranded nucleic acids of 20–100 nucleotides, with high sensitivity and specificity against particular molecular targets. In vitro production and selection of aptamers can be performed using the SELEX method. However, this procedure requires considerable time and cost. In this sense, bioinformatics tools play an important role in reducing the time and cost associated with development and production of aptamers. In this article, we propose bioinformatics strategies for modeling and analysis of the interaction with molecular targets for two RNA aptamers: ATP binding RNA aptamer and iSpinach aptamer. For this purpose, molecular modeling of the tertiary structure of the aptamers was performed with two servers (SimRNA and RNAComposer); and AutoDock Vina and rDock programs were used to dock their respective ligands. The predictions developed with these methods could be used for in silico design of RNA aptamers, through a simple and accessible methodology. Supplemental data for this article is available online at https://doi.org/10.1080/15257770.2021.1951754 .

24 June 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
MRMaritriny Ruaro-Moreno
Maritriny Ruaro-Moreno
GMGloria Paulina Monterrubio
Gloria Paulina Monterrubio
ARAbraham Reyes-Gastellou
Abraham Reyes-Gastellou
JCJuan Castelan-Vega
Juan Castelan-Vega
AAAlicia Jimenez Alberto
Alicia Jimenez Alberto
RRRosa María Ribas-Aparicio
Rosa María Ribas-Aparicio
Tuberculosis is a disease caused by Mycobacterium tuberculosis, representing the second leading cause of death by an infectious agent worldwide. The available vaccine against this disease has insufficient coverage and variable efficacy, accounting for a high number of cases worldwide. In fact, an estimated third of the world’s population has a latent infection. Therefore, developing new vaccines is crucial to preventing it. In this study, the highly antigenic PE_PGRS49 and PE_PGRS56 proteins were analyzed. These proteins were used for predicting T- and B-cell epitopes and for human leukocyte antigen (HLA) protein binding efficiency. Epitopes GGAGGNGSLSS, FAGAGGQGGLGG, GIGGGTQSATGLG (PE_PGRS49), and GTGWNGGKGDTG (PE_PGRS56) were selected based on their best physicochemical, antigenic, non-allergenic, and non-toxic properties and coupled to HLA I and HLA II structures for in silico assays. A construct with an adjuvant (RS09) plus each epitope joined by GPGPG linkers was designed, and the stability of the HLA-coupled construct was further evaluated by molecular dynamics simulations. Although experimental and in vivo studies are still necessary to ensure its protective effect against the disease, this study shows that the vaccine construct is dynamically stable and potentially effective against tuberculosis.

4 November 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MUMaria Magdalena Urzua-Abad
Maria Magdalena Urzua-Abad
AAAlejandra Aquino-Andrade
Alejandra Aquino-Andrade
JCJuan Castelan-Vega
Juan Castelan-Vega
JMJocelin Merida-Vieyra
Jocelin Merida-Vieyra
RRRosa Maria Ribas-Aparicio
Rosa Maria Ribas-Aparicio
GAGerardo Aparicio-Ozores
Gerardo Aparicio-Ozores
Wastewater serves as a reservoir for antimicrobial-resistant bacteria. This study revealed the presence of carbapenem-resistant and carbapenemase-producing Gram-negative bacilli (GNB), established clonal relationships among isolates in hospital and municipal wastewater, and identified a high-risk clone in municipal wastewater. A total of 63 isolates of GNB were obtained, with Enterobacterales being the most frequently isolated group (62%). Carbapenemase-producing Lelliottia amnigena, Kluyvera cryocrescens, and Shewanella putrefaciens isolates were documented for the first time in Mexico. The detectableted carbapenemase genes were blaKPC (55%), blaNDM (12%), blaVIM−2 (12%), blaOXA−48 (4%), blaGES (2%), blaNDM−1 (2%), and blaNDM−5 (2%). Clonal relationships were observed among Klebsiella pneumoniae and Enterobacter spp. isolates, and remarkably the high-risk clone Escherichia coli ST361, carrying blaNDM−5, was identified. This study demonstrates that wastewater harbours carbapenem-resistant and carbapenemase-producing bacteria, posing a public health threat that requires epidemiological surveillance.

11 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
IBIrma Berenice Mulato Briones
Irma Berenice Mulato Briones
IRIsmael Olan Rodriguez-Ildefonso
Ismael Olan Rodriguez-Ildefonso
JJJulián Antonio Jiménez-Tenorio
Julián Antonio Jiménez-Tenorio
PCPatricia Isidra Cauich-Sánchez
Patricia Isidra Cauich-Sánchez
MMMaría del Socorro Méndez-Tovar
María del Socorro Méndez-Tovar
RRRosa María Ribas-Aparicio
Rosa María Ribas-Aparicio
Traditional microbiological methodology is valuable and essential for microbiota composition description and microbe role assignations at different anatomical sites, including cervical and vaginal tissues; that, combined with molecular biology strategies and modern identification approaches, could give a better perspective of the microbiome under different circumstances. This pilot work aimed to describe the differences in microbiota composition in non-cancer women and women with cervical cancer through a culturomics approach combining culture techniques with Vitek mass spectrometry and 16S rDNA sequencing. To determine the possible differences, diverse statistical, diversity, and multivariate analyses were applied; the results indicated a different microbiota composition between non-cancer women and cervical cancer patients. The Firmicutes phylum dominated the non-cancer (NC) group, whereas the cervical cancer (CC) group was characterized by the predominance of Firmicutes and Proteobacteria phyla; there was a depletion of lactic acid bacteria, an increase in the diversity of anaerobes, and opportunistic and non-typical human microbiota isolates were present. In this context, we hypothesize and propose a model in which microbial composition and dynamics may be essential for maintaining the balance in the cervical microenvironment or can be pro-oncogenesis microenvironmental mediators in a process called Ying-Yang or have a protagonist/antagonist microbiota role.

29 April 2024 in Microbiology Research
Verified
Journal Article
Open access
PDF file
APAngie Lizeth Buitrago Pabón
Angie Lizeth Buitrago Pabón
SRSalvador Ruiz
Salvador Ruiz
AAAlicia Jimenez Alberto
Alicia Jimenez Alberto
GAGerardo Aparicio-Ozores
Gerardo Aparicio-Ozores
JCJuan Castelan-Vega
Juan Castelan-Vega
RRRosa María Ribas-Aparicio
Rosa María Ribas-Aparicio
Zika virus (ZIKV) is an emerging flavivirus that represents significant public health challenges, particularly in the Americas, and is a substantial risk to other parts of the world due to its rapid expansion and its established association with neurological disorders, including Guillain–Barré syndrome and an intrauterine fetal infection that can cause microcephaly, blindness, and other congenital neurological complications. To date, no vaccine to prevent ZIKV infections has been approved. Therefore, developing a safe and effective vaccine against this virus is a global health priority. This review analyzes the ZIKV outbreaks, as well as associated neurological complications, its genome, and immunological responses. The current vaccines in development have reported results from preclinical and clinical trials about novel approaches to obtain safer and more effective vaccines and the challenges faced by ZIKV vaccine development.